{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-264000","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2026-06-09T21:04:50+00:00","discovered_at":"2026-06-09T21:06:00.369208+00:00","generated_at":"2026-06-09T21:06:50.684202+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Kyntra Bio receives final $4M holdback from AstraZeneca for China ops sale","bullets":["Received $4.0M from AstraZeneca, satisfying final holdback under February 2025 share purchase agreement.","Total consideration for sale of China operations was ~$220M ($85M enterprise value + ~$135M net cash).","Previously received $6.0M holdback plus $0.4M net cash adjustment payment in November 2025.","With this payment, all owed amounts under the Share Purchase Agreement have been collected."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-264000","json":"https://secwatch.observer/filing/0001193125-26-264000.json","markdown":"https://secwatch.observer/filing/0001193125-26-264000.md","text":"https://secwatch.observer/filing/0001193125-26-264000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000119312526264000/0001193125-26-264000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000119312526264000/kynb-20260602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:06:50.684202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}